Abstract: The approval of macitentan has increased the number of pharmacological treatments of pulmonary arterial hypertension (PAH). Here, we review the effect on PAH of macitentan compared to other endothelin receptor antagonists. Drugs targeting the endothelin (ET) pathway include the selective ET A receptor antagonist ambrisentan, the ET A /ET B receptor antagonists, bosentan and macitentan, which were recently approved for PAH treatment. Macitentan exhibits higher antagonistic potency than bosentan and ambrisentan in pulmonary smooth muscle cells. Compared to ambrisentan and bosentan, macitentan has a longer duration of action, reflected by the longer half-life, as well as pharmacodynamics attributed to its active metabolite, ACT-132577. The efficacy of macitentan on PAH was investigated in the phase III SERAPHIN trial (NCT00660179). Macitentan significantly reduced morbidity and mortality. It improved the 6-min. walk distance (6MWD) among PAH patients. In the AMB-320/321-E (NCT00578786) study, ambrisentan improved exercise capacity. In the EARLY study (NCT00091715), bosentan showed improvements in 6MWD which were not statistically significant. Bosentan had an effect on PAH in patients with Eisenmenger syndrome (ES) in the BREATHE-5 study (NCT00367770), while macitentan did not improve 6MWD in these patients, but there are differences regarding study size and functional class, and that 30% of the patients treated with macitentan were already in treatment with a phosphodiesterase type 5 inhibitor. Macitentan revealed a lower risk of developing peripheral oedema and hepatotoxicity in the SERAPHIN study. In summary, macitentan has an efficiency comparable to bosentan and ambrisentan in the treatment of PAH. Patients treated with macitentan exhibited less adverse effects compared to bosentan and ambrisentan. In patients with PAH associated with ES, the trials with bosentan and macitentan do not seem comparable, and it needs to be clarified whether these drugs are effective when administered as part of a combination treatment in this condition.
Pulmonary arterial hypertension (PAH) is one form of a broader condition known as pulmonary hypertension (PH). It is a rare but very serious condition that can lead to a number of complications (e.g. right ventricular failure) and ultimately a fatal outcome when left untreated [1] . In Denmark, the total annual incidence is approximately 30 new cases [2] , while the prevalence in Europe is estimated to be 15-60 per million [3] .
Throughout the past two decades, several treatment options have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of PAH. In 2013, the FDA approved the promising drug macitentan which is an endothelin (ET) receptor antagonist [4] . Early symptoms of PAH include dyspnoea, fatigue and dizziness [5] . These symptoms are vague and could be linked to numerous other conditions which increases the difficulty of a correct diagnosis of PAH. Due to these diagnostic challenges, the patient investigation should comprise an evaluation of patient history, physical examination, echocardiography, functional tests, for example 6-min. walk distance (6MWD), and right heart catheterization (RHC) [5] .
The aim of the research programme leading to the development of macitentan was to improve the efficacy and safety compared to other ET receptor antagonists (ERAs) [6] . In the present MiniReview, we tested the hypothesis that macitentan shows advantages compared to other ERAs in terms of improved pharmacokinetics, pharmacodynamics and safety profile. To address the hypothesis, we performed a systematic literature search in available databases with the aim of analysing the pharmacokinetics, pharmacodynamics, compliance, contraindications, interactions and adverse effects (AEs) of macitentan and then compare macitentan with other ERAs. Firstly, we summarize background knowledge on PAH, including the definition as well as current treatment options targeting the ET pathway, the nitric oxide pathway and the prostacyclin pathway, and then provide a comprehensive description of the ET pathway together with a clarification of the mechanisms of action of the current clinically available ERAs.
Methods
This MiniReview is written in accordance with the standards described in the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) [7] . The literature used in this MiniReview was identified using online databases and online registers. These included Author for correspondence: Daniela Grimm, Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers All e 4, DK-8000 Aarhus C, Denmark (e-mail dgg@biomed.au.dk).
PubMed (www.ncbi.nlm.nih.gov/pubmed) and clinicaltrials.gov (www.clinicaltrials.gov). Keywords that were used in these databases included 'macitentan', 'PAH', 'macitentan and PAH', 'PH' and 'ERAs and PAH'.
In PubMed, 'Macitentan' produced 203 search results, 'PAH' gave 18,586 results, 'macitentan and PAH' gave 124 results, 'PH' generated 57,570 results, and 'ERAs and PAH' gave 711 results. The most recent PubMed search was executed on 17 April 2018.
Definition of PAH
Pulmonary arterial hypertension is diagnosed when the following haemodynamic criteria are met, according to ESC/ERS guidelines [8] :
• Mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest • Pulmonary capillary wedge pressure (pCWP) ≤15 mmHg Right heart catheterization can confirm the diagnosis by measuring the mPAP and pCWP accurately. Therefore, it is an essential medical procedure in patients with PAH [9] . Previously, there was an exercise criterion (mPAP > 30 mmHg), but this has been removed as it was assessed that healthy people were able to exceed this threshold [10] .
According to the ESC/ERS guidelines, PH can be grouped into five categories, based on aetiology (table 1) [8] . This classification is based on the classification created by the World Health Organization (WHO) in 2013. It is presumed that, in each category, similarities in pathophysiology, histology and treatment are found [11] .
Treatment of PAH
As a curative treatment for PAH has yet to be discovered, the current therapy is only symptomatic and supportive. In some cases, non-pharmacological approaches are needed to treat PAH, including atrial septostomy and lung transplantation [12] .
Current pharmacological treatments primarily target one of the following three pathways which are believed to play a role in the pathogenesis of PAH:
• The nitric oxide/cyclic guanosine monophosphate (cGMP) pathway
• The prostacyclin pathway
• The ET pathway
The nitric oxide/cGMP pathway. Phosphodiesterases (PDEs) are enzymes that degrade the second messengers, cyclic adenosine monophosphate (cAMP) and cGMP which are involved in the nitric oxide signalling pathway to mediate the antiproliferative and vasodilative effects in pulmonary arterial smooth muscle cells (PASMCs) [13] . This antiproliferative effect was demonstrated in studies investigating vascular smooth muscle cells from rat and man [14] [15] [16] . PDE-5 is the prevalent subtype of this class of enzymes (PDEs) in the lung. It is elevated in PAH patients. Accordingly, the mechanism of work of sildenafil and tadalafil is to inhibit PDE-5, thus preventing the interference of this enzyme with the nitric oxide signalling pathway [13] .
Riociguat, approved by the 0 US FDA 0 in 2013, is a soluble guanylate cyclase (sGC) stimulator. The binding of nitric oxide to sGC catalyses the formation of cGMP from GTP in the PASMCs. cGMP activates protein kinase G (PKG), resulting in vasodilative and antiproliferative effects [13, 17] . The antiproliferative effect has been demonstrated in studies investigating cultured rabbit aortic smooth muscle cells [16] .
The prostacyclin pathway. The endogenous prostacyclin (PGI 2 ) production in patients suffering from PAH has been reported to be decreased, likely due to the decreased PGI 2 synthase expression in lung tissue [18] . Normally, prostacyclin and its analogues bind to the prostacyclin (IP) receptor, mediating a number of effects, including vasodilation, antiproliferative and antithrombotic effects. The antiproliferative effect was demonstrated in studies with growth-arrested human adult aortic and foetal smooth muscle cells [15] . Examples of prostacyclin analogues that are widely used in the treatment of PAH are iloprost and selexipag [19] , and other examples are epoprostenol and treprostenil. Iloprost and treprostenil are administered by inhalation, selexipag is administered orally (first FDA-approved prostacyclin analogue that is administered orally), and epoprostenol is administered by infusion [20] due to its relatively short halflife (<6 min.) [21] . The ET pathway. Pulmonary arterial hypertension is associated with elevated levels of ET-1 which is a potent vasoconstrictive biological peptide [22] . ET-1 is produced by vascular endothelium [23] and acts through two subtypes of the ET-1 receptor which are both G protein-coupled receptors (GPCR) and activate the G qmediated signalling pathway [13] : The ET A receptor is G protein-coupled and predominantly found in PASMCs [24] . The binding of ET peptides (ET-1 = ET-2 > ET-3) to ET A receptors activates phospholipase C (PLC) which then hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP 2 ) and lead to the formation of inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG) [25] . IP 3 will subsequently generate an increase in intracellular [Ca 2+ ] by causing a Ca 2+ -release from the sarcoplasmic reticulum, thus facilitating the smooth muscle cell contraction [13] . DAG will activate protein kinase C (PKC), and animal studies suggest that this activation causes an enhanced contraction in vascular smooth muscle. More specifically, PKC is suggested to lead to increased Ca 2+ -sensitivity of the contractile apparatus and thereby facilitates vascular smooth muscle contraction [26, 27] . Furthermore, the activation of ET A receptors induces proliferation of the PASMCs [28] . Based on rat experiments, it has been found that, in smaller pulmonary arteries, the ET B receptor is mainly expressed on PASMCs where it leads to activation of the same signalling pathways as the ET A receptor [29] and also plays a role in the proliferation of PASMCs [28] . In larger pulmonary arteries, however, G protein-coupled ET B receptors are mainly found on endothelial cells (ECs) [30] , and activation of ET B receptors by ET peptides (ET-1 = ET-2 = ET-3) leads to increases in endothelial cell calcium followed by activation of endothelial nitric oxide synthase (eNOS), release of nitric oxide and vasodilatation [31] (fig. 1) .
ET A and ET B receptors are also expressed in cardiomyocytes in the heart and fibroblasts where they contribute to the structural remodelling of the heart and remodelling in the pulmonary circulation [32] . In the right ventricle, the ET A and ET B receptors contribute to the increased risk of cardiac hypertrophy in PAH-suffering patients with elevated levels of ET-1 [33, 34] . Consequently, the expression of the receptors in the right ventricle as well as the presence of circulating ET-1 could contribute to the development of right ventricular failure, a potentially fatal complication of PAH.
Endothelin receptor antagonists used today are either ET Aselective [e.g. sitaxentan, ambrisentan; ( fig. 2A) Macitentan exerts its effects by blocking the ET A and ET B receptors and thereby prevents the effects of ET-1. The ET A receptors are mainly found in PASMCs, while ET B receptors are found in both PASMCs (in smaller arteries) and ECs (in larger arteries). It has been suggested that the binding of ET-1 to its receptors may cause ET A and ET B receptors to form homodimers and heterodimers, but how that affects the signalling pathways activated by the receptors remain unclear [38] . In addition to the antagonism of the ET A and ET B receptors by macitentan, it has been suggested that the dual antagonism occurs due to the ability of the antagonist to prevent heterodimerization of ET A and ET B receptors [39] . The binding of macitentan prevents ET peptides from binding to the receptors and hence attenuates smooth muscle increases in intracellular [Ca 2+ ] and Ca 2+ sensitivity. PAH is associated with proliferation and vasoconstriction causing vascular remodelling in the lungs, and these effects are attenuated by ERAs [13] . Macitentan has expressed slower receptor dissociation compared to other approved ERAs [6] , contributing to its more potent pharmacological effect. Gatfield et al. published a study conducting a comparative assessment of the receptor dissociation kinetics of macitentan, ambrisentan and bosentan. In this study, Ca 2+ release assays were performed on PASMCs. The cells were pre-incubated with Ca 2+ for either 10 min. or 120 min., followed by stimulation with ET-1. Subsequently, the Ca 2+ concentrations were measured. After 120-min. exposure, macitentan exhibited a 6.3-fold potency (K b ratio) increase compared to 10-min. exposure. In contrast, ambrisentan produced a K b ratio of 1.0 by comparing the mean K b values after 10 min. and after 120 min. Finally, the K b ratio for bosentan was assessed to be 0.7 [6] .
Pharmacokinetics
After oral administration (once daily), macitentan is absorbed slowly. It binds strongly to plasma proteins (>99%), mainly albumin [40] , which serve as transporters for macitentan in plasma, as the drug is insoluble in water [22] . No study has yet been performed to specifically investigate the absolute bioavailability. However, via a physiologically based pharmacokinetic model technique, the oral bioavailability has been predicted to be approximately 74% [24] , see table 2. The volume of distribution has been estimated to be 50 L [22] .
The maximum plasma concentration (T max ) is reached approximately 8 hr post-administration. The half-life (T 1/2 ) of macitentan is 16 and 48 hr for ACT-132577.
Macitentan is metabolized by CYP450 enzymes -most importantly CYP3A4, and to a lesser extent by CYP2C19, CYP2C8 and CYP2C9 [40] . It is metabolized to both an active (ACT-132577) and inactive (ACT-373898) metabolites [40] , via oxidative depropylation and oxidative cleavage, respectively [36] . The active metabolite contributes approximately to 40% of the total pharmacological effect [41] .
A significant proportion of the elimination of macitentan is attributed to renal excretion (50%) and faecal excretion (24%) [41] . 
Contraindications
Macitentan as well as other ERAs is contraindicated in pregnant women due to the risk of causing teratogenic damage. The use of effective contraceptives for PAH-suffering women, who undergo treatment with macitentan, has been advised [36] . The FDA has classified the drug into the pregnancy category x [22] , meaning that studies in animals and observations in man have shown the teratogenicity associated with the drug [42] . Thus, similar to bosentan, macitentan shows toxicity to seminiferous tubules, decreases haematocrit and causes craniofacial abnormalities in foetuses exposed in utero, but there are no off-target effects (FDA, NDA204-410, page 3 of 163 Medical Review). It is unknown whether macitentan is excreted into milk, which could cause a risk to the child. In in vivo experiments in rats, macitentan was detected in milk. Thus, the drug should not be administered to breastfeeding women [43] .
According to the European Commission [43] , patients with severe hepatic dysfunction or patients with elevated liver enzymes should not undergo treatment with macitentan. Macitentan treatment is not recommended in patients with moderate hepatic impairment.
Interactions
Pharmacokinetic interactions occur with drugs that strongly induce or inhibit CYP3A4. For example, strong inducers of CYP3A4 (e.g. rifampin, carbamazepine, phenytoin and St. John 0 s Wort) can cause reduced plasma concentration of macitentan. Similarly, strong inhibitors of CYP3A4 (e.g. ketoconazole, itraconazole or ritonavir) increase the plasma concentration of macitentan. It has been claimed that, compared to other approved ERAs, macitentan appears to have fewer interactions with other drugs [22] , but this probably has to be re-evaluated 
Macitentan.
The SERAPHIN trial is the most comprehensive pivotal study conducted on investigating the efficacy of macitentan in the treatment of subjects with PAH. Indeed, the FDA approval of macitentan was primarily based on SERAPHIN data [4] .
SERAPHIN comprised 742 subjects in total, whereof 250 subjects were randomly assigned to receive placebo once daily, 250 to receive 3 mg macitentan once daily and 242 to receive 10 mg macitentan once daily. Moreover, participation required subjects to be above the age of 12. The subjects included in the trial had all been examined using RHC to confirm the diagnosis of PAH. The primary end-point was the time from initiation of the treatment to first incidence of morbidity or mortality. The secondary end-point was a change in 6MWD from baseline to 6 months later [44] .
The mean study duration was 85.3, 99.5 and 103.9 weeks for the placebo group, the 3-mg macitentan group and 10-mg macitentan group, respectively. In the placebo group, 46.4% of the subjects reached the primary end-point (first incidence of morbidity or mortality). In the 3-mg group, the proportion was 38.0%, and in the 10-mg group, it was 31.4%. Comparing the 3-mg macitentan group to the placebo group leads to a hazard ratio (HR) of 0.70 [with a 97.5% confidence interval (CI), 0.52-0.96; p = 0.01]. Comparing the 10-mg macitentan group to the placebo group results in a HR of 0.55 (97.5% CI, 0.32-0.76; p < 0.001) [44] .
At the 6th month, the mean 6MWD in placebo decreased by 9.4 m. In the 3-mg macitentan group, the mean 6MWD increased by 7.4 m [treatment effect versus placebo was estimated to be 16.8 m (97.5% CI, À2.7 to 36.4 m; p = 0.01)]. Finally, in the 10-mg macitentan group, the 6MWD increased by 12.5 m [treatment effect versus placebo was estimated to be 22 m (97.5% CI, 3.2-40.8 m; p = 0.008)] [44] .
The data showed significant improvements in 6MWD, indicating improved exercise capacity as well as a reduction in mortality and morbidity.
Comparison of macitentan with bosentan and ambrisentan in PAH.
The EARLY study is a double-blind, randomized, placebo-controlled trial and investigated the effect of bosentan on 6MWD in mildly symptomatic PAH patients [45] . Subjects aged 12 years or over with a 6MWD of <80% of the normal were included. A total of 185 subjects were studied in total and were randomly assigned to receive either bosentan (n = 93) or placebo (n = 92). The treatment period was 6 months. The change in 6MWD from baseline to the end of the treatment period was measured. The analyses included 168 subjects (80 from the bosentan group and 88 from the placebo group). In the bosentan group, the mean 6MWD increased by 11.2 m (95% CI, À4.6 to 27.0 m). In the placebo group, the mean 6MWD decreased by À7.9 m (95% CI, À24.3 to 8.5 m). Treatment effect versus placebo was estimated to be 19.1 m (95% CI, 3.6-41.8 m; p = 0.0758) [45] . Using the standard p = 0.05 cut-off value makes the treatment effect statistically not significant. One explanation for this result could be that the subjects had higher baseline 6MWD values compared to patients in other studies. This would leave less space for improvement in exercise capacity.
Differences in importance should be mentioned when comparing bosentan with macitentan in terms of the effect on exercise capacity (table 4) . For example, the amount of subjects included in these two studies (EARLY versus SERAPHIN) differed from each other, favouring SERAPHIN in terms of credibility. Moreover, in contrast to macitentan, the treatment effect of bosentan did not show a statistical significance which may be related to different inclusion criteria.
A study evaluating the safety and efficacy of ambrisentan in subjects with PAH was conducted (AMB-320/321-E) [46] . AMB-320/321-E was an optional study for the subjects who participated in either AMB-320 (ARIES-1) or AMB-321 (ARIES-2), including 383 subjects. The subjects were assigned to either placebo, 2.5 mg, 5 mg or 10 mg ambrisentan. Changes in 6MWD from baseline to after 1 and 2 years were assessed. After 1 year, subjects in all treatment groups exhibited an improvement in exercise capacity. For the 2.5-mg group, the mean 6MWD increased by 25 m (95% CI, 5-45 m); for the 5-mg group, the change was +28 m (95% CI, 14-42 m); for the 10-mg group, the change was +37 m (95% CI, 22-52 m) [46] .
Comparing ambrisentan with macitentan (AMB-320/321-E versus SERAPHIN), ambrisentan appears superior with regard to the effects on 6MWD, see table 5. In addition, it is important to mention that, of all three studies, only ambrisentan reached the minimal important difference (MID) in 6MWD, which is defined as 33 m (95% CI, 15-15 m) based on the study conducted by Mathai et al. [47] . This emphasizes the importance of parameters when comparing drugs with each other. Establishing a well-defined threshold facilitates the classification of different drugs according to their efficacy and helps to separate potential/experimental interactions from those deemed clinically relevant.
It is important to mention the differences between AMB-320/321-E and SERAPHIN: 6MWD was measured after 1 year, and in SERAPHIN, it was measured after 6 months. The possibility that longer duration of treatment gives more room for improvements of the exercise capacity cannot be fully excluded. It is also important to note that this study was not placebo-controlled, and therefore, it is not possible to precisely estimate the long-term treatment effects of ambrisentan.
Trials with Macitentan and Bosentan in Eisenmenger Syndrome
The Eisenmenger syndrome (ES) is characterized by the development of PAH with consequent intracardiac right-to-left shunt and hypoxaemia in patients with pre-existing congenital heart disease. A randomized, double-blind, placebo-controlled study, BREATHE-5, was conducted to evaluate the effect of bosentan in patients with ES functional class III [48] . The study lasted 16 weeks. The change in mean 6MWD from baseline to week 16 was measured. The change in mean 6MWD decreased by 9.7 AE 22.3 m in the placebo group (n = 17) and increased by 43.4 AE 8.1 m (n = 37) in the bosentan group. This resulted in a treatment effect of 53.1 m (p = 0.008) [48] . MAESTRO was a phase III trial investigating the efficacy of macitentan in patients with ES. It included 226 subjects (macitentan n = 114; placebo n = 112) above the age of 12 years, where 60% of the patients were in WHO functional group. The primary end-point was a change in 6MWD from baseline to week 16 of the treatment. In the main study, the 6MWD was improved by 19.7 m in the placebo group and by 18.3 m in the macitentan group. The resulting treatment effect was estimated to be À4.7 m (95% CI, À22.8 to 13.5 m; p = 0.6120), and the primary end-point evaluating a change in 6MWD was not met [49] .
The different effect of bosentan and macitentan in patients with ES appears to favour bosentan as the preferred ERA for treatment of ES. However, several major differences need to be pointed out. The WHO functional class of ES was different apparently including patients with more severe disease in the BREATHE versus the MAESTRO study, and the number of patients treated in the BREATHE study was small. Moreover, 27% of the patients in the MAESTRO study were already in treatment with a phosphodiesterase inhibitor before the treatment with macitentan. The latter may contribute with bias regarding the effect of macitentan as the treatment with a phosphodiesterase inhibitor may already have had effect on reversible components of the disease or due to more attention to patients in a clinical trial, the treatment with the phosphodiesterase inhibitor has been optimized in the trial period. On the other hand, in the SERAPHIN trial of PAH, the effect of macitentan was similar in patients without and with existing treatment, suggesting that, in this patient population, there is an advantage of combination treatment [50] . Thus, in patients with PAH associated with ES, there is limited information. The trials with bosentan and macitentan do not seem comparative, and it needs to be clarified whether these drugs have effects when administered as part of a combination treatment Table 5 . Comparison of 6-min. walk distance (6MWD) estimates and common adverse effects (AEs) between bosentan, ambrisentan and macitentan from the EARLY, BREATHE-5, AMB-320/321-E and SERAPHIN studies.
Bosentan [45, 48] Ambrisentan [46] Macitentan [ 
Assessment of Adverse Effects of Macitentan, Bosentan and Ambrisentan
The phase III SERAPHIN trial demonstrated that macitentan was generally well tolerated, and the common AEs associated with macitentan were mild. Common AEs described for 3 mg macitentan included nasopharyngitis (14.8% compared to placebo 10.4%), headache (13.2% compared to 8.8%) and anaemia (8.8% compared to 3.2%), where a significant increase in the incidence of the above-mentioned AEs compared to the placebo group was registered [44] .
In AMB-320/321-E, the most common AEs observed for ambrisentan were peripheral oedema, headache, upper respiratory infection and dizziness. The discontinuation rates due to AEs were similar in the three dose groups (between 5% and 6%) [46] .
In the EARLY study, the most common AEs observed for bosentan were nasopharyngitis and abnormal liver function. The discontinuation rates were equal in the placebo and treatment groups [45] . Furthermore, the BREATHE-5 study showed that AEs occurring more commonly in the treatment group than in the placebo group included peripheral oedema (19% versus 6%), headache (14% versus 12%), palpitations (11% versus 0%), dizziness (8% versus 6%) and chest pain (8% versus 0%) [48] . See table 5 for a comparison of the most common AEs among bosentan, ambrisentan and macitentan.
Other ERAs are known to cause peripheral oedema and hepatotoxicity, but the SERAPHIN trial did not show any significant increase in incidence of these AEs compared to placebo [44] . It has been evidenced that bosentan, as well as its three metabolites, can cause liver damage by inhibiting the canalicular bile salt export pump [51] . It has also been demonstrated that macitentan does not interact with the transport of hepatic bile salt. Accordingly, the drug has showed a more advantageous liver safety profile compared to bosentan [52, 53] .
As previously mentioned, ERAs are known for causing AEs such as peripheral oedema and hepatotoxicity [54] . Macitentan seems to be better tolerated than its FDA-approved competitors, bosentan and ambrisentan. In the SERAPHIN trial, no remarkable difference in liver enzyme levels was identified between macitentan and placebo. In addition, the incidence of peripheral oedema was similar between all groups [44] . Moreover, it is interesting to note that the proportions of the subjects in each category (placebo, 3 mg macitentan and 10 mg macitentan) that discontinued the study due to AEs were 12.4% (31), 13.6% (34) and 10.7% (26) , respectively. This suggests that AEs caused by macitentan play a minimal role in reducing the compliance of PAH-suffering patients. Other properties of macitentan can play a role in treatment compliance: for example, administration (once-daily oral for macitentan versus twice-daily oral for bosentan) and the fewer drug-drug interactions compared to bosentan [55] . Similar to macitentan, ambrisentan is also metabolized by CYP3A4 and via glucuronidation and hence has the same drug interactions as macitentan. So far, there are no studies focusing on the treatment compliance of macitentan.
The SERAPHIN study made it possible to assess the efficacy of macitentan in combination therapy in PAH. In Jansa et al., these assessments have been performed. Patients receiving macitentan as well as background therapy (other PAH therapies) showed increased efficacy in terms of exercise capacity, functional class, cardiopulmonary haemodynamics and health-related quality of life (QOL) compared with background therapy only. Furthermore, macitentan reduced morbidity/mortality by 38% in patients who were on background therapy, compared to placebo (HR = 0.62, 95% CI, 0.43-0.89; p = 0.009) [50] .
A meta-analysis conducted by Wei et al. [54] to analyse the AEs of ERAs included 4894 subjects from 24 randomized, double-blind, placebo-controlled trials. It showed that bosentan was associated with a significantly increased risk of abnormal liver function compared to placebo [12.30% versus 4.47%; risk ratio (RR) = 3.79, 95% CI, 2.42-5.91; p = 0.002]. No association was found for macitentan or ambrisentan. The association with peripheral oedema was assessed as well, and the comparative analyses demonstrated that bosentan compared to placebo had a significant increased risk of developing peripheral oedema (10.3% versus 7.1%; RR = 1.47, 95% CI, 1.06-2.03; p = 0.02), but also a significantly increased risk was found in ambrisentan compared to placebo (20.8% versus 10.3%; RR = 2.02, 95% CI, 1.40-2.91; p = 0.0002) [54] .
Anaemia, an AE associated with macitentan as well as bosentan was evaluated in SERAPHIN. The results indicate a dose-dependent association between macitentan and the incidence of anaemia (incidence of anaemia in placebo, 3 mg macitentan and 10 mg macitentan was 3.2%, 8.8% and 13.2%, respectively) [44] .
In summary, these studies demonstrated that macitentan causes less AEs that commonly occur in patients treated with ERAs, including peripheral oedema and hepatotoxicity. This strongly indicates a more favourable AE profile compared to bosentan and ambrisentan.
Conclusions
Macitentan targets the ET pathway and has demonstrated beneficial effects in the treatment of PAH compared to other FDA-approved ERAs, including bosentan and ambrisentan. Macitentan exhibits pharmacokinetic and pharmacodynamic advantages which have been evidenced in both pre-clinical as well as clinical studies. The advantages include fewer drugdrug interactions, prolonged receptor binding properties, a better tissue penetration, higher antagonistic potency and a milder AE profile. However, the clinical effects of the higher antagonistic potency of macitentan compared to ambrisentan remain unclear. Compared to ambrisentan and bosentan, macitentan for unknown reasons appears to be associated with less occurrence of lower peripheral oedema. Bosentan is further associated with an increased incidence of hepatotoxicity. Macitentan does not interact with hepatic cellular transporters involved in ERA-induced elevation of hepatic enzymes that lead to a decrease in transaminitis, a health condition with elevated levels of liver transaminases in clinical trials.
Macitentan has shown to significantly reduce morbidity and mortality, as well as to increase the exercise capacity measured by a 6MWD. The finding that ambrisentan seems to show better improvements of 6MWD compared to macitentan (SERAPHIN versus AMB-320/321-E) is questionable due to differences in the study designs. In the EARLY study, bosentan showed improvements in the 6MWD, but the results did not reach statistical significance. In patients with PAH associated with ES, the trials with bosentan and macitentan do not seem comparative, and it needs to be clarified whether these drugs are effective when administered as part of a combination treatment in this condition.
Outlook
Despite the emergence of new effective drugs, no curative therapy for PAH exists. Consequently, PAH remains to be a significant medical condition that requires attention and further investigations. Despite the advantages that macitentan has shown compared to bosentan and ambrisentan, some questions still have to be addressed. These questions include the efficacy of macitentan in children with PAH and in patients with ES where no significant efficacy was shown in patients with the latter condition, according to results from the MAESTRO trial.
Future trials should assess changes in functional capacity and long-term prognosis of PAH-suffering patients who are in treatment with macitentan.
